| Name | Title | Contact Details |
|---|---|---|
James Doherty |
General Counsel | Profile |
Michael Garofola |
Deputy General Counsel | Profile |
NextGen Pharma Technologies is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Diaceutics believe that every patient should get the treatment they deserve. We have worked on every Precision Medicine brought to market and we are trusted by the worlds leading pharmaceutical companies. Find out about DXRX - the Diagnostic Network f...
Eddingpharm Group Co. is a Carrboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Citizens Rx provides pharmacy benefit management services to public and private companies and offers health plans in the United States.